Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...6970717273747576777879...136137»
  • ||||||||||  dimethyl fumarate / Generic mfg.
    Review, Journal:  Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology. (Pubmed Central) -  Feb 17, 2022   
    To date, there has been no evidence suggesting that treatment with fingolimod, dimethyl fumarate, or natalizumab leads to antibody deficiency...Immune supplementation employing Ig replacement therapy might reduce morbidity and mortality associated with SIDs in neurological conditions. In light of the broad range of existing and emerging therapies, the potential for SID warrants urgent consideration among neurologists and other healthcare professionals.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Entyvio (vedolizumab) / Takeda
    Biomarker, Clinical, Observational data, Retrospective data, Review, Journal:  Durable Metastatic Melanoma Remission Following Pembrolizumab and Radiotherapy: A Case Report of Prophylactic Immunosuppression in a Patient with Myasthenia Gravis and Immune-Mediated Colitis. (Pubmed Central) -  Feb 17, 2022   
    Here, we report a case of a 75-year-old man with myasthenia gravis and metastatic melanoma who experienced complete and durable systemic regression after receiving pembrolizumab and single-lesion RT while on prednisone for myasthenia gravis prophylaxis and vedolizumab for immune-mediated colitis after previously experiencing mixed response on pembrolizumab monotherapy. We discuss the potential paradoxical effects and clinical considerations of immunosuppressive regimens in patients with underlying autoimmune disease or adverse immune reactions while receiving immuno-radiotherapy combinations.
  • ||||||||||  Journal:  Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature. (Pubmed Central) -  Feb 16, 2022   
    Both signature Th subsets rebounded in the blood of MG patients after surgical thymus removal, indicative of their role as cellular markers of disease activity. Together, this in-depth analysis of the immune landscape of MG provides valuable insight into disease pathogenesis, suggests novel biomarkers and identifies new potential therapeutic targets for treatment.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Journal:  Nivolumab-related myasthenia gravis with myositis requiring prolonged mechanical ventilation: a case report. (Pubmed Central) -  Feb 15, 2022   
    Although immune checkpoint inhibitor-related myasthenia gravis is a rare adverse event, appropriate and prompt treatment is required because of its severity and rapid progression. Diaphragm ultrasound was useful not only in diagnosing diaphragm dysfunction and deciding the strategy for weaning from mechanical ventilation but also in evaluating the recovery of the diaphragmatic function.
  • ||||||||||  Industry Therapeutic Update from UCB, Inc.: MG. What lies beneath? The MG pathophysiology forum () -  Feb 14, 2022 - Abstract #AAN2022AAN_614;    
    These programs are not an official part of the 2022 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.
  • ||||||||||  Biomarker, Review, Journal:  Role of Toll-Like Receptors in Neuroimmune Diseases: Therapeutic Targets and Problems. (Pubmed Central) -  Feb 11, 2022   
    Herein, we provide an overview of the role of TLRs in several neuroimmune diseases, including multiple sclerosis, neuromyelitis optica spectrum disorder, Guillain-Barré syndrome and myasthenia gravis. Emerging difficulties and potential solutions in clinical application of TLRs inhibitors will also be discussed.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Clinical, Review, Journal:  Eculizumab treatment for myasthenia gravis subgroups: 2021 update. (Pubmed Central) -  Feb 11, 2022   
    Despite the efficacy of eculizumab in treating AchR antibody-positive refractory gMG was demonstrated in the REGAIN study, there is few information on its efficacy in other subgroup of MG patients including seronegative MG, thymoma-associated MG and MG crisis. This narrative review summarizes current clinical studies of eculizumab in these refractory gMG patients, with a focus on the therapeutic efficacy and tolerability in different subgroup of MG.
  • ||||||||||  Review, Journal:  Therapeutic Plasma Exchange: For Cancer Patients. (Pubmed Central) -  Feb 11, 2022   
    In addition, the issues of side-effects and safety in the use of therapeutic plasma exchange are also discussed. However, well-designed prospective trials are needed to better define the role of therapeutic plasma exchange in cancer.
  • ||||||||||  Thymoma: a single centre, 10-year retrospective review ([VIRTUAL]) -  Feb 9, 2022 - Abstract #BTOG2022BTOG_240;    
    Whilst there was some variation in management detected, the European guidelines were largely adopted. A larger national cohort is being investigated.
  • ||||||||||  Journal:  Expanding the Role of the Pharmacist: Immunoglobulin Therapy and Disease Management in Neuromuscular Disorders. (Pubmed Central) -  Feb 8, 2022   
    Pharmacists with a good understanding of current recommendations, dosing strategies, and administration routes for IgG therapy are best placed to support patients. The aims of this review are to highlight the evidence supporting IgG therapy in the treatment of NMDs and provide practical information on patient management and IVIg/SCIg dosing in order to guide pharmacists on optimizing clinical outcomes and patient care.
  • ||||||||||  fluoxetine / Generic mfg.
    Journal:  Treatment of slow-channel congenital myasthenic syndrome in a Thai family with fluoxetine. (Pubmed Central) -  Feb 8, 2022   
    Here we report a prospective open label study of fluoxetine treatment in some affected members of a Thai family with slow-channel congenital myasthenic syndrome caused by a novel p.Gly153Ala (c.518G > C) mutation in CHRNA1 in the AChR α subunit. These patients showed significant clinical improvement following fluoxetine treatment but their respiratory function responded variably.
  • ||||||||||  Clinical, Journal:  Coincident parkinsonism and myasthenia gravis: A case series. (Pubmed Central) -  Feb 5, 2022   
    These patients showed significant clinical improvement following fluoxetine treatment but their respiratory function responded variably. After querying our institution's electronic health record system for patients with primary parkinsonism and myasthenia gravis (MG), we report the cases of 15 patients with Parkinson disease and MG, and a case of Dementia with Lewy Bodies and MG.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Retrospective data, Review, Journal:  Different Monoclonal Antibodies in Myasthenia Gravis: A Bayesian Network Meta-Analysis. (Pubmed Central) -  Feb 5, 2022   
    As an emerging therapy, monoclonal antibodies are prospective in the treatment of MG. However, more researches are required to be invested in the future as the results obtained from small sample sizes are not reliable enough.
  • ||||||||||  Review, Journal:  Surgery for recurrent thymoma during the COVID-19 pandemic: a narrative review. (Pubmed Central) -  Feb 5, 2022   
    It is possible to offer surgery with low risk of perioperative COVID infection and related morbidity and mortality. Given the benefits seen in survival and disease-free survival, we believe surgery for recurrent thymoma should continue to be advocated even during the current viral pandemic.
  • ||||||||||  Preclinical, Journal:  A Task Based Learning (TskBL) strategy in preclinical medical education. (Pubmed Central) -  Feb 4, 2022   
    Tutorial group did not show a significant improvement in test scores for all the tasks.TskBL strategy could be used for many other topics are likely to be encountered by the students during clinical attachments. Small group teaching can include TskBL over tutorials to provide early clinical exposure in medical schools.
  • ||||||||||  Clinical, Journal:  Survival, Prognosis, and Clinical Feature of Refractory Myasthenia Gravis: a 15-year Nationwide Cohort Study. (Pubmed Central) -  Feb 3, 2022   
    BTZ represents a proteasome inhibitor that can potentially be used to treat AD patients resistant to conventional therapies. Despite the severe prognosis of rMG, the strategies for pharmacotherapeutic regimens were similar in those two groups, suggesting that intensive monitoring and introduction of timely treatment options in the early phase of MG are required.
  • ||||||||||  Review, Journal:  Congenital myasthenic syndromes: where do we go from here? (Pubmed Central) -  Feb 3, 2022   
    The list of genes harbouring disease-causing mutations for congenital myasthenic syndrome continues to expand and is now over 30, but with many of the newly identified genes it is increasingly being recognised that abnormal neuromuscular transmission is only one component of a multifaceted phenotype in which muscle, the central nervous system, and other organs may also be affected. Treatment can be tailored to the underlying molecular mechanism for impaired neuromuscular transmission but treating the more complex multifaceted disorders and will require development of new therapies.
  • ||||||||||  Clinical, Review, Journal:  Primary mitochondrial myopathies in childhood. (Pubmed Central) -  Feb 3, 2022   
    A rare cause of isolated myopathy in children, reversible infantile respiratory chain deficiency myopathy, is non-progressive and typically associated with spontaneous full recovery. Promising targeted treatments have been reported for a number or mitochondrial myopathies including riboflavin in ACAD9 and ETFDH-myopathies and deoxynucleoside for TK2-related disease.